Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia-Reference-Cited by-同舟云学术

Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

Published:2015-12 Issue:11 Volume:78 Page:754-762
ISSN:0006-3223
Container-title:Biological Psychiatry
language:en
Short-container-title:Biological Psychiatry

Author:

Kinon Bruce J.,Millen Brian A.,Zhang Lu,McKinzie David L.

Publisher

Elsevier BV

Subject

Biological Psychiatry

Reference32 articles.

1. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial;Patil;Nat Med,2007

2. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders;Krystal;Harv Rev Psychiatry,1999

3. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia;Goff;Am J Psychiatry,2001

4. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology;Paz;Eur Neuropsychopharmacol,2008

5. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia;Jentsch;Neuropsychopharmacology,1999

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders;International Journal of Molecular Sciences;2024-06-13

2. Identifying drug targets for schizophrenia through gene prioritization;2024-05-16

3. Novel Inhibitory Site Revealed by XAP044 Mode of Action on the Metabotropic Glutamate 7 Receptor Venus Flytrap Domain;Journal of Medicinal Chemistry;2024-05-01

4. Pharmacologic and genetic evidence converge on mechanisms of psychotic illness;2024-05-01

5. The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia;Biochemical Pharmacology;2024-05